Industry

Reflects continued progress in the business combination process; transaction is expected to be completed during the second half of 2022 SAN DIEGO & NORCROSS, Ga.–(BUSINESS WIRE)–Viveon Health Acquisition Corp. (NYSE: VHAQ) (“Viveon Health” or “VHAQ”), a special purpose acquisition company, and Suneva Medical, Inc. (“Suneva” or the “Company”), an innovative medical technology company using regenerative … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Pharmacy Benefit Management Market in the US – Industry Outlook & Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The U.S. pharmacy benefit management market is expected to grow at a CAGR of 5.53% during 2022-2027 The study considers a detailed scenario of the present U.S. pharmacy benefit management market and its … [Read more…]

BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it has named Chris Morabito, M.D., as Chief Medical Officer. Dr. Morabito brings more than 20 years of clinical development experience in rare diseases and other … [Read more…]

Enhances alignment with US shareholder base and other peer biotechnology companies Positions company for growth while helping to reduce complexity and certain administrative costs The Company’s name, brand, and ticker symbol to remain unchanged VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the company will present new data that highlight the development of its highly selective, context-dependent TGFβ1 antibody that inhibits proTGFβ1 activation selectively in the context … [Read more…]

ISS Recommends Common Shareholders Vote in Favor of Proposals 1 and 2 Discussed Below ATLANTA–(BUSINESS WIRE)–Regional Health Properties, Inc. (NYSE American: RHE) (NYSE American: RHE-PA) (“RHE,” “we” or the “Company”) reminds its common shareholders to vote at the upcoming special meeting (the “Special Meeting”) to be held on Monday, July 25, 2022 at 10:00 a.m., … [Read more…]

EVANSTON, Ill.–(BUSINESS WIRE)–Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business … [Read more…]

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces record sales of Avenova-branded products during Amazon’s Prime Day event (July 12-13). Sales of Avenova-branded products during the two-day event increased 27% over Prime Days 2021 and 48% over Prime Days 2020, and … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Elastase Inhibitor – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering. “Elastase Inhibitor – Pipeline Insight, 2022” offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Elastase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report by Product Type (Tablets, Capsules), by Mechanism (Controlled-, Immediate-release), by End-user, by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The global oral solid dosage contract manufacturing market size is expected to reach USD 54.7 billion … [Read more…]